Kevin R Coffey1, Atom J Lesiak2, Russell G Marx1, Emily K Vo1, Gwenn A Garden3, John F Neumaier1. 1. Puget Sound VA Health Care System and Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, 98105, USA. 2. Department of Genome Sciences, University of Washington School of Medicine, Seattle, WA, 98105, USA. 3. Department of Neurology, University of North Carolina, Chapel Hill, NC, 27599, USA.
Abstract
Background: Microglia have recently been implicated in opioid dependence and withdrawal. Mu Opioid (MOR) receptors are expressed in microglia, and microglia form intimate connections with nearby neurons. Accordingly, opioids have both direct (MOR mediated) and indirect (neuron-interaction mediated) effects on microglia function. Methods: To investigate this directly, we used RNA sequencing of ribosome-associated RNAs from striatal microglia (RiboTag-Seq) after the induction of morphine tolerance and followed by naloxone precipitated withdrawal (n=16). We validated the RNA-Seq data by combining fluorescent in-situ hybridization with immunohistochemistry for microglia (n=18). Finally, we expressed and activated the Gi/o-coupled hM4Di DREADD receptor in CX3CR1-expressing cells during morphine withdrawal (n=18). Results: We detected large, inverse changes in RNA translation following opioid tolerance and withdrawal. WGCNA analysis revealed an intriguing network of cAMP-associated genes that are known to be involved in microglial motility, morphology, and interactions with neurons that were downregulated with morphine tolerance and upregulated rapidly by withdrawal. Three-dimensional histological reconstruction of microglia allowed for volumetric, visual colocalization of mRNA within individual microglia that validated our bioinformatics results. Direct activation of Gi/o-coupled DREADD receptors in CX3CR1-expressing cells exacerbated signs of opioid withdrawal rather than mimicking the effects of morphine. Conclusions: These results indicate that Gi-signaling and cAMP-associated gene networks are inversely engaged during opioid tolerance and early withdrawal, perhaps revealing a role of microglia in mitigating the consequences of opioids.
Background: Microglia have recently been implicated in opioid dependence and withdrawal. Mu Opioid (MOR) receptors are expressed in microglia, and microglia form intimate connections with nearby neurons. Accordingly, opioids have both direct (MOR mediated) and indirect (neuron-interaction mediated) effects on microglia function. Methods: To investigate this directly, we used RNA sequencing of ribosome-associated RNAs from striatal microglia (RiboTag-Seq) after the induction of morphine tolerance and followed by naloxone precipitated withdrawal (n=16). We validated the RNA-Seq data by combining fluorescent in-situ hybridization with immunohistochemistry for microglia (n=18). Finally, we expressed and activated the Gi/o-coupled hM4Di DREADD receptor in CX3CR1-expressing cells during morphine withdrawal (n=18). Results: We detected large, inverse changes in RNA translation following opioid tolerance and withdrawal. WGCNA analysis revealed an intriguing network of cAMP-associated genes that are known to be involved in microglial motility, morphology, and interactions with neurons that were downregulated with morphine tolerance and upregulated rapidly by withdrawal. Three-dimensional histological reconstruction of microglia allowed for volumetric, visual colocalization of mRNA within individual microglia that validated our bioinformatics results. Direct activation of Gi/o-coupled DREADD receptors in CX3CR1-expressing cells exacerbated signs of opioid withdrawal rather than mimicking the effects of morphine. Conclusions: These results indicate that Gi-signaling and cAMP-associated gene networks are inversely engaged during opioid tolerance and early withdrawal, perhaps revealing a role of microglia in mitigating the consequences of opioids.
Authors: Nicole E Burma; Robert P Bonin; Heather Leduc-Pessah; Corey Baimel; Zoe F Cairncross; Michael Mousseau; Jhenkruthi Vijaya Shankara; Patrick L Stemkowski; Dinara Baimoukhametova; Jaideep S Bains; Michael C Antle; Gerald W Zamponi; Catherine M Cahill; Stephanie L Borgland; Yves De Koninck; Tuan Trang Journal: Nat Med Date: 2017-01-30 Impact factor: 53.440
Authors: Heather Leduc-Pessah; Nicholas L Weilinger; Churmy Y Fan; Nicole E Burma; Roger J Thompson; Tuan Trang Journal: J Neurosci Date: 2017-09-18 Impact factor: 6.167
Authors: Mark R Hutchinson; Susannah S Lewis; Benjamen D Coats; David A Skyba; Nicole Y Crysdale; Debra L Berkelhammer; Anita Brzeski; Alexis Northcutt; Christine M Vietz; Charles M Judd; Steven F Maier; Linda R Watkins; Kirk W Johnson Journal: Brain Behav Immun Date: 2008-10-04 Impact factor: 7.217
Authors: Gregory Corder; Vivianne L Tawfik; Dong Wang; Elizabeth I Sypek; Sarah A Low; Jasmine R Dickinson; Chaudy Sotoudeh; J David Clark; Ben A Barres; Christopher J Bohlen; Grégory Scherrer Journal: Nat Med Date: 2017-01-16 Impact factor: 53.440
Authors: Ana Badimon; Hayley J Strasburger; Pinar Ayata; Xinhong Chen; Aditya Nair; Ako Ikegami; Philip Hwang; Andrew T Chan; Steven M Graves; Joseph O Uweru; Carola Ledderose; Munir Gunes Kutlu; Michael A Wheeler; Anat Kahan; Masago Ishikawa; Ying-Chih Wang; Yong-Hwee E Loh; Jean X Jiang; D James Surmeier; Simon C Robson; Wolfgang G Junger; Robert Sebra; Erin S Calipari; Paul J Kenny; Ukpong B Eyo; Marco Colonna; Francisco J Quintana; Hiroaki Wake; Viviana Gradinaru; Anne Schaefer Journal: Nature Date: 2020-09-30 Impact factor: 69.504